Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study

@article{AndrSchmutz2002ImmuneRW,
  title={Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study},
  author={Isabelle Andr{\'e}-Schmutz and Françoise le Deist and Salima Hacein-Bey-Abina and Ellen S. Vitetta and John Schindler and Ga{\"e}lle Ch{\'e}deville and Etienne Vilmer and Alain Fischer and Marina Cavazzana‐Calvo},
  journal={The Lancet},
  year={2002},
  volume={360},
  pages={130-137}
}
BACKGROUND Allogeneic haemopoietic stem-cell transplantation (HSCT) is the treatment of choice for many haematological malignancies and inherited disorders. When stem cells for transplantation come from a human leucocyte antigen matched unrelated donor, or from a partly mismatched related donor, ex-vivo T-cell depletion of the graft can prevent development of graft-versus-host disease, but lead in turn to a delay in immune reconstitution and a concordant increase in incidence of opportunistic… Expand
Specific removal of alloreactive T-cells to prevent GvHD in hemopoietic stem cell transplantation: rationale, strategies and perspectives.
TLDR
Different approaches to deplete alloreactive T-cells only are reviewed and pros and cons, specificity, efficiency and efficacy are discussed, and Combinations of different methods and innovative approaches are also proposed for depleting specific allore active T- cells with high efficiency. Expand
Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation
TLDR
Reconstitution of HSCT recipients with antigen-specific T cells, produced either by allodepletion or in vitro reactivation, can offer an effective strategy to provide both immediate and long-term protection without harmful alloreactivity. Expand
Improving immune reconstitution while preventing GvHD in allogeneic stem cell transplantation.
TLDR
Several strategies are being optimized specifically to inactivate anti-host T cells while preserving anti-leukemic or anti-microbial immunocompetence, which have been explored extensively in pre-clinical studies and tested in some preliminary clinical trials. Expand
Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.
TLDR
The results suggest that allodepletion of donor cells ex vivo is clinically feasible in older patients and may reduce the rate of severe acute GVHD. Expand
Superior depletion of alloreactive T cells from peripheral blood stem cell and umbilical cord blood grafts by the combined use of trimetrexate and interleukin-2 immunotoxin.
TLDR
A novel strategy is reported that simultaneously induces 2 independent pathways of apoptosis after stimulation by recipient dendritic cells or Epstein-Barr virus-transformed B cells and selectively depletes proliferating alloreactive precursors in vitro in a dose- and time-dependent manner. Expand
T Cell Immunotherapy for Immune Reconstitution and GVHD Prevention After Allogeneic Hematopoietic Stem Cell Transplantation
TLDR
This review will focus on donor lymphocyte infusion as well as more complex cellular therapies that require extensive cell manipulation that have been envisaged and successfully tested in pilot trials in the early post-transplantation period. Expand
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
TLDR
The current protocol for the generation of peripheral blood mononuclear cells (PBMC) which have been alloanergized to HLA-mismatched unrelated stimulator PBMC is described, which can be easily standardized for clinical use to generate donor T cells with reduced alloreactivity but retaining pathogen-specific immunity for adoptive transfer in the setting of AHSCT to improve immune reconstitution without excessive GvHD. Expand
In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation.
TLDR
A combination of ex vivo and in vivo T- cell depletion, although inhibiting GvHD, prolongs the interval of T cell deficiency after HSCT and favors rejection and infections, implying that the requirement for this type of extensive T-cell depletion should be carefully re-evaluated. Expand
Identification and monitoring of graft-versus-host specific T-cell clone in stem cell transplantation
TLDR
This work identified an alloreactive CD4+ T-cell clone from a donor before stem cell transplantation, and then monitored its frequency in the recipient's peripheral blood after transplantation by use of clonotypic quantitative real-time PCR. Expand
Alloreactive and leukemia-reactive T cells are preferentially derived from naïve precursors in healthy donors: implications for immunotherapy with memory T cells
TLDR
Memory T-cell subsets of most healthy individuals showed decreased allogeneic HLA-reactivity, but lacked significant anti-leukemia responses in vitro, suggesting that the clinical use of memory or naïve-depleted T cells might be beneficial for Hla-mismatched patients at high risk of graft-versus-host disease and low risk of leukemia relapse. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Improving immune reconstitution while preventing graft-versus-host disease in allogeneic stem cell transplantation.
TLDR
Several strategies are being optimized to specifically inactivate anti-host T cells while preserving antileukemic or antimicrobial immunocompetence, based on ex vivo or in vivo elimination of anti- Host T cells or on the modulation of their anti- host activity. Expand
Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis
TLDR
The alloreactive cells are easily recoverable in this selective T cell depletion strategy for cryopreservation and ready for immediate access as therapeutic donor lymphocyte infusions in cases of frank relapse post transplant. Expand
SPECIFIC ELIMINATION OF ALLOREACTIVE T CELLS BY AN ANTI‐INTERLEUKIN-2 RECEPTOR B CHAIN‐SPECIFIC IMMUNOTOXIN
TLDR
The limiting-dilution analysis of residual alloantigen-reactive T lymphocytes has shown that this depletion results in a twentyfold to fiftyfold reduction of antihost reactivity, and inhibitions of these responses may represent useful approaches for screening functional T cell depletion in experimental bone marrow transplantation studies. Expand
Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation : Effect of patient age and donor leukocyte infusions
TLDR
It is demonstrated that adult recipients of TCD unrelated BMTs experience prolonged and profound deficiencies of CD3(+, CD4(+), and CD8(+) T-cell populations when compared with pediatric recipients of unrelated B MT and adults after related BMT, and that these adults have a significantly increased risk of life-threatening opportunistic infections. Expand
Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.
TLDR
The main limitations of transplantation of bone marrow from donors who are matched with the recipient for only one HLA haplotype GVHD and graft failure - can be overcome. Expand
Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease.
TLDR
It is demonstrated that restoration of CMV-specific CTL responses may require an extended time period after BMT in some patients, and that such patients are at increased risk of developing severe CMV disease. Expand
Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients.
TLDR
Results of this retrospective analysis should lead to new protocols adapted to SCID disease, considering that disease-related as well as BMT-related parameters influence the development of immune function and thereby long-term outcome after HLA-nonidentical T-cell-depleted BMT. Expand
Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
TLDR
Results from the combined use of the two MoAbs indicates a trend toward better engraftment and survival after infusion of E rosette-depleted marrow, which would demand additional strategies to hasten immunologic recovery. Expand
Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.
TLDR
Transplantation of marrow from a related donor is a life-saving and life-sustaining treatment for patients with any type of severe combined immunodeficiency, even when there is no HLA-identical donor. Expand
Feasibility of Immunotherapy of Relapsed Leukemia With Ex Vivo–Generated Cytotoxic T Lymphocytes Specific for Hematopoietic System-Restricted Minor Histocompatibility Antigens
TLDR
Ex vivo–generated HA-1– and HA-2–specific CTLs efficiently lyse leukemic cells derived from acute myeloid leukemia (AML) and acute lymphoids leukemia (ALL) patients with a low risk of GVHD are presented. Expand
...
1
2
3
4
...